{'fraction_non_alphanumeric': 0.04436860068259386, 'fraction_numerical': 0.017064846416382253, 'mean_word_length': 6.394957983193278, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Dihydrotestosterone prevents spontaneous adenocarcinomas in the prostate‐seminal vesicle in aging L‐W rats

Gene‐regulated mechanisms govern tumor development, but the actual development of tumors can be suppressed or promoted by epigenetic factors. Lobund‐Wistar (L‐W) rats are genetically predisposed to development of spontaneous and induced metastasizing moderately differentiated adenocarcinomas in the prostate‐seminal vesicle (P‐SV) complex. In L‐W rats with one slow‐release subcutaneous implant of dihydrotestosterone (DHT) (5α‐Androstan‐17β‐ol‐3‐one), the development of induced P‐SV tumors 14 months later was significantly suppressed, with involution of testes, aspermia, and absence of detectable serum testosterone. The tumor‐suppressive effect of DHT was confirmed. Spontaneous P‐SV tumors developed in 57 of 220 control L‐W rats (26%) at an average age 20 months.